The subsequent research should focus on the development, application, and combination of PI3K inhibitors with immunotherapeutic agents, the recognition of predictive biomarkers for the therapeutic response, and the evaluation of how such regulation of this pathway can affect the complicated interactions among tumor cells, stromal factors, and immunological elements. The gene discussed is PIK3CB; the disease is neoplasm.